Last updated 18:35:03
HK$151.00
+57.19%
- Listing price
- HK$96.06
- Open
- —
- High
- —
- Low
- —
- Bid / Ask
- — / —
- Volume
- —
Turnover —View source
LONGBIO-B
0177918AListed醫療健康 · 一家专注于过敏及自身免疫性疾病领域的生物制药公司，致力于创新药物的研发与商业化。
LONGBIO-B (天辰生物－Ｂ) (01779) is a listed Hong Kong IPO. This page brings together the offer price, entry fee, subscription timeline, grey-market context, allotment data and stage-based reference research in one place.
- Offer price
- HK$96.06
- Final offer price
- HK$96.06
- One-lot win rate
- 2.0%
- Proceeds
- HK$1.36B
- Public oversub.
- 4762.6x
Predicted 2.5%
Lot / entry fee 50 shares · HK$5K · Sponsor Sinolink Securities
- Offer starts May 28
- /Offer closes Jun 2
- /Grey market Jun 4
- /Listing Jun 5Now
SubscriptionLONGBIO-B: subscription-stage reference
The subscription stage draws on the prospectus, sponsor record and early public filings. Allotment results and grey-market prints have not occurred yet.
Earlier stage- Reference rating
- High attention
- Reference score
- 75.7
- Forecast grey range
- 0.0% – +164.8%
Pre-greyLONGBIO-B: pre-grey-market reference
The pre-grey stage includes published allotment and public oversubscription data. Grey-market prints are not yet reflected here.
Earlier stage- Reference rating
- High attention
- Reference score
- 78.9
- Forecast grey range
- 0.0% – +163.5%
Post-greyLONGBIO-B: post-grey-market reference
The post-grey stage includes grey-market price and turnover observations. Listing-day results still follow official trading and company announcements.
Current- Reference rating
- High attention
- Reference score
- 81.9
- Forecast first-day range
- +47.9% – +131.6%
View factors and research
Model forecastListing-day trendStrong positiveUp probability 97.9%
Published outcome check
First-day resultBig up+37.2%
Our call: Trend call valid
Covered 19/25 core factors
UsedMissingNot yet scorableN/A
Margin oversubscription
High heatOffer size
Weaker qualityCornerstone lockup
Strong supportPost-lockup offer value
Medium scarcityRecent same-rule trend
Strong trendRecent same-type trend
Strong trendRecent sector trend
Strong trendValuation
Average appealFundamental quality
Average qualityGrowth quality
—Profitability
Weak qualityCash runway
High qualityCustomer concentration
—Cornerstone quality
Strong supportSponsor record
Strong recordGreenshoe arrangementGreenshoe: yes · 15%
Average supportStabilizer track record
—A-share pre-grey trend
—A-share listing-day trend
—Public oversubscription
High heatOne-lot win rate
High heatInternational placing
High heatFinal pricing position
—Actual greenshoe useCumulative use 0.0%
Good supportGrey market return
Strong trendThe assessment and probability ranges are informational only and are not investment advice.
AI Research Report
Post-greyThe analysis report for this IPO is being generated.
LONGBIO-B: grey-market trend
LONGBIO-B: predicted allotment
Only key tiers are shown here. Full tiers and other allotment-pattern comparisons are on the allotment-odds page.
- 1 lot
- 2.5%
- A tail · Apply 1,000 lots
- 0.15 lots
- B head · Apply 1,200 lots
- 0.19 lots
- Top hammer
- 0.99 lots
Predicted
Official
2.0%
Predicted
Official
0.18 lots
Predicted
Official
0.24 lots
Predicted
Official
1.21 lots
Most likely allotment pattern：Larger Pool A applications get less extra allotment；Pool B allotment declines gradually with sizeView full allotment-odds research
How to read this page
These answers combine this IPO’s published figures with clearly labeled model estimates. They explain how to read the modules above and are not investment advice.
What is the one-lot allotment rate for LONGBIO-B?
Public allotment filings put the official one-lot rate at 2.0%, versus this site's pre-allotment model estimate of 2.5%. It is an observation for a 1-lot application, not a guaranteed result.
What is the difference between A-tail and B-head for LONGBIO-B?
Based on the prospectus's legal application tiers, A-tail is 1,000 lots and B-head is 1,200 lots, representing about HK$4.8M and HK$5.8M of application principal. Official average allotment was 0.18 lots and 0.24 lots, versus pre-allotment model estimates of 0.15 lots and 0.19 lots. Pool A and Pool B are allocated separately, so application size alone does not show capital efficiency.
Can the grey-market price of LONGBIO-B be treated as the listing price?
The compiled grey-market observation is about +56.6%, versus +37.2% on the listing day. Grey-market prints are pre-listing sentiment from public sources, not the official opening price.
Why does LONGBIO-B have three reference ratings?
The current status is "Listed", so start with the post-grey section. Subscription, pre-grey and post-grey each use only the public information available at that point, so the score can change. Labels are high attention / neutral / caution only — informational comparison, not a buy or subscribe call.